# US 2021/0330767 A1 · Composition for the treatment of covid-19 infection, and a method of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330767 A1
- Document ID: US20210330767A1
- Status: Published application
- Kind: A1
- Application number: 17/365,925
- Filed: 2021-07-01
- Published: 2021-10-28
- Earliest claimed: 2021-04-08
- Assignees: AntiCancer, Inc.
- Inventors: Qinghong Han; Robert Hoffman
- Web page: https://patentgrep.com/patent/US20210330767A1

## CPC

- A61K 38/51: Lyases (4)
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/55: Protease inhibitors
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 35/00: Antineoplastic agents
- C12N 9/88: Lyases (4.)
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- C12Y 404/01011: Methionine gamma-lyase (4.4.1.11)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Oral composition and a method for the treatment of coronaviruses infections in humans and animals. The method includes the steps of administering orally a methionine cleaving-enzyme; administering orally or parentally a protease inhibitor; and orally administering pyridoxal-L-phosphate in a fluid.

## Claims

### Claim 1

A method for treating coronavirus infection in living beings, the method comprising the steps of:
administering, orally, a composition comprising methioninase enzyme; and
administering, orally, a fluid comprising pyridoxal-L-phosphate.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method further comprises the steps of:
upon administering the methioninase enzyme, administering, orally or parentally, a protease inhibitor.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the methioninase enzyme is a recombinant L-methionine α-deamino-γ-mercaptomethane lyase.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the protease inhibitor is orally administered, the protease inhibitor is a serine- or cysteine-protease inhibitor.

### Claim 5 (depends on 4)

The method according to claim 4, wherein a combination of the serine- and cysteine-protease inhibitors are administered.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the serine protease inhibitor is Carmostat mesylate and the cysteine protease inhibitor is E-64d.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the protease inhibitor is parentally administered, the protease inhibitor is a serine- or cysteine-protease inhibitor.

### Claim 8 (depends on 7)

The method according to claim 7, wherein a combination of the serine- and cysteine-protease inhibitors are administered.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the composition further comprises flavors, sweeteners, and binders.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.

### Claim 11

A method for treating coronavirus infection in living beings, the method comprises the steps of:
administering, orally, a composition comprising methioninase enzyme and an oral protease inhibitor; and
administering, orally, a fluid comprising pyridoxal-L-phosphate.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the methioninase enzyme is a recombinant L-methionine α-deamino-γ-mercaptomethane lyase.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the protease inhibitor is a serine- or cysteine-protease inhibitor.

### Claim 14 (depends on 13)

The method according to claim 13, wherein a combination of the serine- and cysteine-protease inhibitors are administered.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the serine protease inhibitor is Carmostat mesylate and the cysteine protease inhibitor is E-64d.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the composition further comprises flavors, sweeteners, and binders.

### Claim 17 (depends on 11)

The method according to claim 11, wherein the fluid is a solution of pyridoxal-L-phosphate in drinking water.
